"14110" . "59542" . "adherence; persistence; hypertension; perindopril"@en . . "Adherence v l\u00E9\u010Db\u011B hypertenze"@cs . . . "1"^^ . "Adherence v l\u00E9\u010Db\u011B hypertenze"@cs . "I" . "Adherence v l\u00E9\u010Db\u011B hypertenze" . . "Adherence v l\u00E9\u010Db\u011B hypertenze" . "Patient cooperation is essential for the success of treatment. When evaluating the relationship between the patient to treat distinguish persistence, which is defined as the duration of treatment from start to interrupt her, and adherence, which is defined as the proportion of drugs that have actually used the total number of prescribed medications. Adherence is affected by many factors, particularly the amount of tablets, disease severity, duration of treatment and the patient's age. Non-adherence to the treatment of hypertension resulted in poor control of hypertension and impaired cardiovascular risk. In clinical practice, it is therefore necessary to take advantage of opportunities that improve adherence. These options include the use of available fixed combinations of antihypertensive drugs that reduce the amount of tablets and, more recently, the use of orodisperse tablet that simplify the use of the product. The Czech Republic is currently available orodisperse form of perindopril arginine."@en . "1"^^ . . . "2" . "Spolupr\u00E1ce pacienta je nezbytn\u00FDm p\u0159edpokladem \u00FAsp\u011Bchu l\u00E9\u010Dby. P\u0159i hodnocen\u00ED vztahu pacienta k l\u00E9\u010Db\u011B rozli\u0161ujeme perzistenci, kterou definujeme jako dobu trv\u00E1n\u00ED l\u00E9\u010Dby od jej\u00EDho zah\u00E1jen\u00ED do p\u0159eru\u0161en\u00ED, a adherenci, kterou definujeme jako pod\u00EDl l\u00E9k\u016F, kter\u00E9 byly skute\u010Dn\u011B u\u017Eity z celkov\u00E9ho mno\u017Estv\u00ED p\u0159edepsan\u00FDch l\u00E9k\u016F. Adherence je ovlivn\u011Bna \u0159adou faktor\u016F, zejm\u00E9na mno\u017Estv\u00EDm u\u017E\u00EDvan\u00FDch tablet, z\u00E1va\u017Enost\u00ED onemocn\u011Bn\u00ED, dobou l\u00E9\u010Dby a v\u011Bkem pacienta. Non-adherence m\u00E1 v l\u00E9\u010Db\u011B hypertenze za n\u00E1sledek \u0161patnou kontrolu hypertenze a zhor\u0161en\u00ED kardiovaskul\u00E1rn\u00EDho rizika. V klinick\u00E9 praxi je proto t\u0159eba vyu\u017E\u00EDt mo\u017Enost\u00ED, kter\u00E9 adherenci zlep\u0161uj\u00ED. Mezi tyto mo\u017Enosti pat\u0159\u00ED vyu\u017E\u00EDv\u00E1n\u00ED dostupn\u00FDch fixn\u00EDch kombinac\u00ED antihypertenziv, kter\u00E9 sni\u017Euj\u00ED mno\u017Estv\u00ED u\u017E\u00EDvan\u00FDch tablet a nov\u011Bji i pou\u017Eit\u00ED orodisperzn\u00EDch tablet, kter\u00E9 zjednodu\u0161uj\u00ED u\u017E\u00EDv\u00E1n\u00ED p\u0159\u00EDpravku. V \u010Cesk\u00E9 republice je v sou\u010Dasnosti dostupn\u00E1 orodisperzn\u00ED forma perindopril argininu."@cs . . "Adherence in the treatment of hypertension"@en . . . "Spolupr\u00E1ce pacienta je nezbytn\u00FDm p\u0159edpokladem \u00FAsp\u011Bchu l\u00E9\u010Dby. P\u0159i hodnocen\u00ED vztahu pacienta k l\u00E9\u010Db\u011B rozli\u0161ujeme perzistenci, kterou definujeme jako dobu trv\u00E1n\u00ED l\u00E9\u010Dby od jej\u00EDho zah\u00E1jen\u00ED do p\u0159eru\u0161en\u00ED, a adherenci, kterou definujeme jako pod\u00EDl l\u00E9k\u016F, kter\u00E9 byly skute\u010Dn\u011B u\u017Eity z celkov\u00E9ho mno\u017Estv\u00ED p\u0159edepsan\u00FDch l\u00E9k\u016F. Adherence je ovlivn\u011Bna \u0159adou faktor\u016F, zejm\u00E9na mno\u017Estv\u00EDm u\u017E\u00EDvan\u00FDch tablet, z\u00E1va\u017Enost\u00ED onemocn\u011Bn\u00ED, dobou l\u00E9\u010Dby a v\u011Bkem pacienta. Non-adherence m\u00E1 v l\u00E9\u010Db\u011B hypertenze za n\u00E1sledek \u0161patnou kontrolu hypertenze a zhor\u0161en\u00ED kardiovaskul\u00E1rn\u00EDho rizika. V klinick\u00E9 praxi je proto t\u0159eba vyu\u017E\u00EDt mo\u017Enost\u00ED, kter\u00E9 adherenci zlep\u0161uj\u00ED. Mezi tyto mo\u017Enosti pat\u0159\u00ED vyu\u017E\u00EDv\u00E1n\u00ED dostupn\u00FDch fixn\u00EDch kombinac\u00ED antihypertenziv, kter\u00E9 sni\u017Euj\u00ED mno\u017Estv\u00ED u\u017E\u00EDvan\u00FDch tablet a nov\u011Bji i pou\u017Eit\u00ED orodisperzn\u00EDch tablet, kter\u00E9 zjednodu\u0161uj\u00ED u\u017E\u00EDv\u00E1n\u00ED p\u0159\u00EDpravku. V \u010Cesk\u00E9 republice je v sou\u010Dasnosti dostupn\u00E1 orodisperzn\u00ED forma perindopril argininu." . "[91BAF44D7376]" . . "Sou\u010Dek, Miroslav" . "Hypertenze & kardiovaskul\u00E1rn\u00ED prevence" . . . "CZ - \u010Cesk\u00E1 republika" . . "2"^^ . "Adherence in the treatment of hypertension"@en . "RIV/00216224:14110/13:00068387" . . "RIV/00216224:14110/13:00068387!RIV14-MSM-14110___" . "1805-4129" . . . "4" .